

# Pharmakologische Interaktionen bei der antiretroviralen Therapie

Hartwig Klinker, Würzburg

**Arzneimitteltherapie 2005;23:80–8.**

## Literatur

- Antoniou T, Lin-in Tseng A. Interactions between recreational drugs and antiretroviral agents. *Ann Pharmacother* 2002;36:1598–1613.
- Barry MG, Merry C, Lloyd J, Halifax K, et al. Variability in through plasma saquinavir concentrations in HIV patients: a case for therapeutic drug monitoring. *Br J Clin Pharmacol* 1998;45:501–2.
- Bart PA, Rizzardi PG, Gallant S, et al. Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir. *Ther Drug Monit* 2001;23:553–5.
- Csajka C, Marzolini C, Fattinger K, Decosterd LA, et al. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. *Clin Pharmacol Ther* 2003;73:20–30.
- Damle BD, Mummaneni V, Kaul S, Knupp C. Lack of effect of simultaneously administered didanosine encapsulated enteric bead formulation (Videx EC) on oral absorption of indinavir, ketoconazole, or ciprofloxacin. *Antimicrob Agents Chemother* 2002;46:385–91.
- Dasgupta A, Okhuysen PC. Pharmacokinetic and other drug interactions in patients with AIDS. *Ther Drug Monit* 2001;23:591–605.
- de Maat MMR, Ekhardt GC, Huitema ADR, Koks CHW, et al. Drug interactions between antiretroviral drugs and comedicated agents. *Clin Pharmacokinet* 2003;42:223–82.
- Dieleman JP, Gyssens IC, van der Ende ME, de Marie S, et al. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. *AIDS* 1999;13:473–8.
- Dionisio D, Mininni S, Bartolozzi D, Esperti F, et al. Need for increased dose of warfarin in HIV patients taking nevirapine. *AIDS* 2001;15:277–8.
- Fellay J, Marzolini C, Meaden ER, Back DJ, et al. Response to antiretroviral treatment in HIV-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. *Lancet* 2002;359:30–6.
- Fichtenbaum CJ, Gerber JG, Rosenkranz SL, Segal Y, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG study A5047. *AIDS* 2002;16:569–77.
- Foster BC, Foster MS, Vandenhoeck S, Krantiz A, et al. An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. *J Pharm Pharmacol Sci* 2001;4:176–84.
- Hoetelmans RM, Reijers MH, Weverling GJ, ten Kate RW, et al. The effect of plasma drug concentrations on HIV clearance rate during quadruple drug therapy. *AIDS* 1998;12:111–5.
- Hsu A, Granneman GR, Cao G, Carothers L, et al. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. *Clin Pharmacol Ther* 1998;63:453–64.
- Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. *Clin Pharmacokinet* 2004;43:595–612.
- Klinker H, Langmann P. Therapeutisches Drug-Monitoring in der HIV-Therapie. In: Jäger H (Hrsg.). *AIDS und HIV-Infektionen. Handbuch und Atlas für Klinik und Praxis*. Landsberg: Ecomed Verlagsgesellschaft, 2003:1987ff,II–5.3,1–18.
- Langmann P, Klinker H, Schirmer D, Zilly M, et al. High-performance liquid chromatographic method for the simultaneous determination of HIV-1 protease inhibitors indinavir, saquinavir and ritonavir in plasma of patients during highly active antiretroviral therapy. *J Chromatogr B* 1999;735:41–50.
- Langmann P, Schirmer D, Väh T, Zilly M, et al. High-performance liquid chromatographic method for the simultaneous determination of HIV-1 non-nucleoside reverse transcriptase inhibitor efavirenz in plasma of patients during highly active antiretroviral therapy. *J Chromatogr B* 2001;755:151–6.
- Marzolini C, Buclin T, Decosterd LA, Biollaz J, et al. Nelfinavir plasma levels under twice-daily and three-times-daily regimens: high interpatient and low inpatient variability. *Ther Drug Monit* 2001;23:394–8.
- Merry C, Barry MG, Ryan M, Zjia JF, et al. Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. *AIDS* 1999;13:F101–7.
- Piscitelli SC, Gallicano KD. Drug therapy: interactions among drugs for HIV and opportunistic infections. *N Engl J Med* 2001;344:984–96.
- Reijers MH, Weigel HM, Hart AA, Ten Kate RW, et al. Toxicity and drug exposure in a quadruple drug regimen in HIV-1 infected patients participating in the ADAM study. *AIDS* 2000;14:59–67.
- Sadler BM, Gillotin C, Lou Y, Stein DS. In vivo effect of alpha(1)-acid glycoprotein on pharmacokinetics of amprenavir, a human immunodeficiency virus protease inhibitor. *Antimicrob Agents Chemother* 2001;45:852–6.
- Schapiro JM, Winters MA, Stewart F, Efron B, et al. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. *Ann Intern Med* 1996;124:1039–50.
- Sim SM, Hoggard PG, Sales SD, Phiboonbanakit D, et al. Effect of ribavirin on zidovudine efficacy and toxicity in vitro: a concentration-dependent interaction. *AIDS Res Hum Retroviruses* 1998;20:1661–7.
- Smith PF, DiCenzo R, Morse GD. Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. *Clin Pharmacokinet* 2001;40:893–905.
- Veldkamp AI, Harris M, Montaner JSG, Moyle G, et al. The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1 infected persons. *J Infect Dis* 2001;184:37–42.
- Yeni PG, Hammer SM, Hirsch MS, Saag MS, et al. Treatment for adult HIV infection. Recommendations of the International AIDS-Society USA-Panel, 2004. *JAMA* 2004;292:251–65.

**Prof. Dr. Hartwig Klinker, Medizinische Poliklinik der Universität, Standort Luitpoldkrankenhaus, Schwerpunkt Hepatologie/Infektiologie, Josef-Schneider-Str. 2, 97080 Würzburg, E-Mail: klinker\_h@klinik.uni-wuerzburg.de**